AU2003239357B2 - Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms - Google Patents

Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms Download PDF

Info

Publication number
AU2003239357B2
AU2003239357B2 AU2003239357A AU2003239357A AU2003239357B2 AU 2003239357 B2 AU2003239357 B2 AU 2003239357B2 AU 2003239357 A AU2003239357 A AU 2003239357A AU 2003239357 A AU2003239357 A AU 2003239357A AU 2003239357 B2 AU2003239357 B2 AU 2003239357B2
Authority
AU
Australia
Prior art keywords
nucleic acid
prostate cancer
diagnostic marker
cancer antigen
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003239357A
Other languages
English (en)
Other versions
AU2003239357A1 (en
Inventor
Youji Hu
Mark Stearns
Min Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philadelphia Health and Education Corp
Original Assignee
Philadelphia Health and Education Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philadelphia Health and Education Corp filed Critical Philadelphia Health and Education Corp
Publication of AU2003239357A1 publication Critical patent/AU2003239357A1/en
Application granted granted Critical
Publication of AU2003239357B2 publication Critical patent/AU2003239357B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003239357A 2002-05-07 2003-05-07 Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms Ceased AU2003239357B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/140,602 US7790861B2 (en) 1999-09-24 2002-05-07 Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
US10/140,602 2002-05-07
PCT/US2003/014098 WO2003094844A2 (en) 2002-05-07 2003-05-07 Prostate cancer-related compositions, methods, and kits based on dna macroarray proteomics platforms

Publications (2)

Publication Number Publication Date
AU2003239357A1 AU2003239357A1 (en) 2003-11-11
AU2003239357B2 true AU2003239357B2 (en) 2010-05-20

Family

ID=29418388

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003239357A Ceased AU2003239357B2 (en) 2002-05-07 2003-05-07 Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms

Country Status (8)

Country Link
US (1) US7790861B2 (enExample)
EP (1) EP1507787B1 (enExample)
JP (2) JP2006518182A (enExample)
AT (1) ATE534654T1 (enExample)
AU (1) AU2003239357B2 (enExample)
CA (1) CA2484845A1 (enExample)
RU (1) RU2004133036A (enExample)
WO (1) WO2003094844A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007035766A2 (en) * 2005-09-19 2007-03-29 The Johns Hopkins University Biomarker for prostate cancer
JP2007222160A (ja) * 2006-01-26 2007-09-06 National Institute Of Advanced Industrial & Technology 生体由来試料中の蛋白質の解析方法
US20090136465A1 (en) 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
CN101469348B (zh) * 2008-08-29 2011-07-20 苏州福英基因科技有限公司 一种前列腺癌症早期的原位杂交检测试剂盒及其检测方法和应用
JP6941565B2 (ja) 2015-05-12 2021-09-29 ドレクセル ユニバーシティ がん転移を処置または防止するのに有用な化合物および組成物、ならびにこれらの使用法
CN108659062B (zh) * 2018-04-18 2021-06-22 中国农业科学院兰州畜牧与兽药研究所 唾液酸寡糖-磁纳米酶及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021828A1 (en) * 1999-09-24 2001-03-29 Philadelphia, Health And Education Corporation A pcam-1 marker protein, nucleic acid sequences encoding pcam-1 and immunoassays for detection of pcam-1
WO2001057190A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2002311778A1 (en) * 2001-03-21 2002-10-28 Philadelphia Health And Education Corporation Prostate cancer-related compositions, methods and kits based on dna macroarray protemics platforms

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763209A (en) 1988-09-26 1998-06-09 Arch Development Corporation Methods and materials relating to the functional domains of DNA binding proteins
US5578444A (en) 1991-06-27 1996-11-26 Genelabs Technologies, Inc. Sequence-directed DNA-binding molecules compositions and methods
US6066452A (en) 1997-08-06 2000-05-23 Yale University Multiplex selection technique for identifying protein-binding sites and DNA-binding proteins
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US7749695B2 (en) * 2003-03-03 2010-07-06 Alexander Abbas PRO polypeptides for diagnosis of systemic lupus erythematosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021828A1 (en) * 1999-09-24 2001-03-29 Philadelphia, Health And Education Corporation A pcam-1 marker protein, nucleic acid sequences encoding pcam-1 and immunoassays for detection of pcam-1
WO2001057190A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2002311778A1 (en) * 2001-03-21 2002-10-28 Philadelphia Health And Education Corporation Prostate cancer-related compositions, methods and kits based on dna macroarray protemics platforms

Also Published As

Publication number Publication date
RU2004133036A (ru) 2005-06-27
JP2006518182A (ja) 2006-08-10
WO2003094844A3 (en) 2004-09-10
EP1507787A4 (en) 2006-04-19
EP1507787B1 (en) 2011-11-23
US7790861B2 (en) 2010-09-07
ATE534654T1 (de) 2011-12-15
AU2003239357A1 (en) 2003-11-11
US20030100033A1 (en) 2003-05-29
WO2003094844A2 (en) 2003-11-20
CA2484845A1 (en) 2003-11-20
EP1507787A2 (en) 2005-02-23
JP2010131022A (ja) 2010-06-17

Similar Documents

Publication Publication Date Title
US8206899B2 (en) Prostate cancer-related compositions, methods and kits based on DNA microarray proteomics platforms
JP4458551B2 (ja) 哺乳類アポトーシス抑制性蛋白質遺伝子ファミリー、プライマー、プローブおよび検出法
JP4404381B2 (ja) Ｐｓｃａ：前立腺幹細胞抗原
DK2081586T4 (en) Rspondins as modulators of angiogenesis and vasculogenesis
WO1997030108A1 (en) Characterized brca1 and brca2 proteins and screening and therapeutic methods based on characterized brca1 and brca2 proteins
JP2002512602A (ja) 増殖性疾患の診断および治療のためのｉａｐ類およびｎａｉｐの検出および調節
JP2010131022A (ja) Ｄｎａマクロアレイプロテオミクスプラットフォームに基づく前立腺癌関連組成物、方法およびキット
US6884619B2 (en) Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
JP4005135B2 (ja) 神経アポトーシス抑制性蛋白質（ｎａｉｐ）の使用
US20050059120A1 (en) Compositions, methods, and kits relating to resistin-like molecules
US7754435B2 (en) Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
US20100047868A1 (en) Tumour Suppressor Protein
JPH10146195A (ja) 良性前立腺肥大と関連するポリヌクレオチドおよびポリペプチド
US20030049651A1 (en) Tumor associated proteins
US20030207339A1 (en) PCAM-1 marker protein, nucleic acid sequences encoding PCAM-1 and immunoassays for detection of PCAM-1
AU2002318241B2 (en) Inhibition of behab cleavage and primary central nervous system (CNS) tumors
AU2002318241A1 (en) Inhibition of behab cleavage and primary central nervous system (CNS) tumors
US20100184843A1 (en) Identification of a pin specific gene and protein (pin-1) useful as a diagnostic treatment for prostate cancer

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 18, NO 2, PAGE(S) 568 UNDER THE HEADING APPLICATIONS OPI NAME INDEX UNDER THE NAME PHILADELPHIA HEALTH AND EDUCATION CORPORATION(D/B/A MCP HAHNEMANN UNIVERSITY), APPLICATION NO. 2003239357, UNDER INID (43) CORRECT THE PUBLICATION DATE TO READ 24 NOVEMBER 2003

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired